«

»

Aug 03

Now have two studies in the journal Cell.

Meanwhile IAP antagonist ‘ chemicals kill tumorsChemical compounds designed specifically to proteins that allow otherwise would tumor cells to neutralize cheat death were for some time by scientists a promising new a promising new strategies for cancer therapy. Now have two studies in the journal Cell, a publication of Cell Press, an insight into how these antagonists of the anti – death – so-called inhibitor-of – apoptosis – proteins work to fight tumors.

Elliott, Heidi JA Wall Weber, Flygare, Wayne J. Fairbrother, Kurt Deshayes, Vishva M. Dixit , and Domagoj Vucic, of Genentech, South San Francisco.

Improvements in China Heart Care According To study neededunjust and cost inefficient allocation of scarce resources it was found that being a major problem in the treatment of heart attack and severe angina patients in China, announced the results of a study presented today at the World Congress of Dr.

The results from the Clinical Pathways for the management of Acute Coronary Syndrome project , which by the Chinese Society by the Chinese Society of Cardiology and the George Institute for International Health develops to examine how patients with acute coronary syndromes are managed in hospitals across China..Presented the results in the study at a future international cancer congress on U.S. With one eye on of new indications marketed for new indications.

Bowel Cancer Drugs Meet Phase III endpointSwitzerland pharmaceutical company Roche said Monday its cancer medicines Avastin and Xeloda had fulfills primary endpoint in a late-stage degree for metastatic colorectal cancer.. The study indicates that the combination Xeloda and Xelox as effectively as FOLFOX if rival drug on 2,035 previously untreated patients was tested.

And Avastin, a drug that inhibit the growth blood vessel feed cancer cells, at the stage III trial , the period, that patient better without any progression of the disease if the adding chemotherapy survived either type.